Clinical Trial to Evaluate Efficacy and Safety of ROVASRO 10mg Versus CRESTOR 10mg in Hypercholesterolemic Patients

Inclusion Criteria: 1. Individuals aged between 19 and 80 years old. 2. The following patients who belong to the low-risk group to the very-high risk group according to 2015 Korean guidelines for the management of dyslipidemia (Committee, KCJ 2016). * Very high risk group (coronary artery disease, ischemic stroke, peripheral vascular disease) were not receiving lipid-lowering agents (statins) within 4 weeks of the screening, regardless of LDL-C levels * High risk group (carotid artery disease, abnormal aneurysm, diabetes)\* : LDL-C ≥ 100 mg/dl * Moderate risk group (2 or more major risk factors)\* : LDL-C ≥ 130 mg/dl * Low risk group (less than 1 major risk factors)\* : LDL-C ≥ 160 mg/dl * If the patients taka a lipid-lowering agents (statin) within 4 weeks of screening, enrolled them after wash-out for 4 weeks or more. 3. Patients who voluntarily participated in the trial and obtained document consent. Exclusion Criteria: 1. a history of acute arterial disease (patients with unstable angina myocardial infarction, transient ischemic attack, cerebrovascular disease, coronary artery bypass graft or percutaneous transluminal coronary angioplasty within 3 months prior to study enrollment) 2. uncontrolled hypertension (systolic blood pressure ≥180mmHg or diastolic blood pressure ≥100mmHg) 3. uncontrolled diabetes (hemoglobin A1c ≥9% or fasting glucose ≥160mg/dl) 4. uncontrolled thyroid dysfunction (thyroid stimulation hormone ≥1.5 times the upper limits of normal (ULN)) 5. usage of antihyperlipidemic drugs (bile acid sequestrants, fibrates, niacin, etc.) within 4 weeks before enrollment 6. a history of myopathy, rhabdomyolysis or elevated serum creatinine kinase (CK) more than 2 times the ULN 7. chronic kidney disease (serum creatinine ≥2 times the ULN) 8. elevated liver enzymes (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2 times the ULN) 9. a history of drug or alcohol abuse 10. a history of gastrointestinal surgery or gastrointestinal tract disorders 11. hypersensitivity to the components of this drug 12. those who disagree with contraception 13. pregnancy and/or lactation.